This product is suitable for use with the?Maxpar? Metal Labeling Kits.?For metal labeling using Maxpar? Ready antibodies,?proceed directly to the step to Partially Reduce the Antibody by adding 100 ?l of Maxpar? Ready antibody to 100 ?l of 4 mM TCEP-R in a 50 kDa filter and continue with the protocol. Always refer to the latest version of Maxpar? User Guide when conjugating Maxpar? Ready antibodies.

The 3G8 antibody clone blocks neutrophil phagocytosis and stimulates NK cell proliferation. It has been reported that this clone interacts with the FcγRIIa and FcγRIIIb receptors causing neutrophil activation and aggregation¹⁸. Due to this phenomenon staining in whole blood may cause a reduction in the number of granulocytes or alter their scatter profile.

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections⁶, immunoprecipitation³, stimulation of NK cell proliferation⁴, blocking of phagocytosis⁵, and blocking of immunoglobulin binding to FcγRIII^7,8. The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 302049, 302050, 302057, 302058).

Maxpar? is a registered trademark of Standard BioTools Inc.

1. Knapp W, et al. Eds. 1989. Leucocyte Typing IV. Oxford University Press. New York.
2. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
3. Edberg J, et al. 1997. J. Immunol. 159:3849. (IP)
4. Hoshino S, et al. 1991. Blood 78:3232. (Stim)
5. Tamm A, et al. 1996. Immunol. 157:1576. (Block)
6. Da Silva DM, et al. 2001. Int. Immunol. 13:633. (IHC)
7. Holl V, et al. 2004. J. Immunol. 173:6274. (Block)
8. Hober D, et al. 2002. J. Gen. Virol. 83:2169. (Block)
9. Brainard DM, et al. 2009. J. Virol. 83:7305. PubMed
10. Smed-S?rensen A, et al. 2008. Blood 111:5037. (Block) PubMed
11. Timmerman KL, et al. 2008. J. Leukoc. Biol. 84:1271. (FC) PubMed
12. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
13. Rout N, et al. 2010. PLoS One 5:e9787. (FC)
14. Kim WK, et al. 2006. Am. J. Pathol. 168:822. (FC)
15. Boltz A, et al. 2011. J. Biol Chem. 286:21896. PubMed
16. Wu Z, et al. 2013. J. Virol. 87:7717. PubMed
17. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
18. Vossebeld PJ, et al. 1997. Biochem J. 323:87-94 (Stim)

1. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
2. Wei SC et al. 2017. Cell. 170(6):1120-1133 . PubMed
3. Fenton TM, et al. 2020. Immunity. 52(3):557-570. PubMed
4. Jordan S, et al. 2020. Cell. 178(5):1102-1114.e17.. PubMed

NK cells, activated monocytes, macrophages, neutrophils

1. Fleit H, et al. 1982. P. Natl. Acad. Sci. USA 79:3275.
2. Stroncek D, et al. 1991. Blood 77:1572.
3. Wirthmueller U, et al. 1992. J. Exp. Med. 175:1381.